AMF Tjanstepension AB Has $55.21 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

AMF Tjanstepension AB increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.8% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 138,350 shares of the medical equipment provider’s stock after purchasing an additional 3,826 shares during the quarter. AMF Tjanstepension AB’s holdings in Intuitive Surgical were worth $55,214,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ISRG. Vanguard Group Inc. increased its stake in shares of Intuitive Surgical by 0.7% in the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after acquiring an additional 196,316 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Edgewood Management LLC raised its stake in shares of Intuitive Surgical by 7.9% during the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Intuitive Surgical by 2.0% during the 4th quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after buying an additional 88,977 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at approximately $1,313,238,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Down 0.1 %

Intuitive Surgical stock traded down $0.26 during mid-day trading on Friday, reaching $444.85. The company had a trading volume of 3,106,093 shares, compared to its average volume of 1,525,986. The firm has a market cap of $157.79 billion, a price-to-earnings ratio of 80.30, a PEG ratio of 5.72 and a beta of 1.39. The company has a 50 day moving average of $403.83 and a 200-day moving average of $382.69. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $447.11.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the business earned $1.00 earnings per share. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the transaction, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of Intuitive Surgical stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $385.55, for a total transaction of $92,146.45. Following the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,123,223.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 175 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the transaction, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,956 shares of company stock valued at $6,927,011. 0.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of analyst reports. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Jefferies Financial Group boosted their price target on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Finally, Robert W. Baird lowered their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $403.67.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.